Mode
Text Size
Log in / Sign up

14-3-3 proteins function as potential but unvalidated biomarkers and therapeutic targets in colorectal cancerNew research identifies potential protein markers for colorectal cancer

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that 14-3-3 isoforms are currently testable hypotheses and not clinically validated targets in colorectal cancer.

This narrative review synthesizes the roles of 14-3-3/YWHA proteins (YWHAG, YWHAE, YWHAZ, YWHAB, YWHAH, and SFN) in colorectal cancer. The authors describe specific mechanisms for various isoforms: YWHAG is linked to CTTN-dependent Wnt/beta-catenin activation; YWHAE is associated with extracellular-vesicle secretion and a competing endogenous RNA mechanism for KRAS/ERK and PI3K/AKT signaling; and YWHAZ participates in epithelial-mesenchymal and G2/M transitions. Additionally, YWHAB supports PIK3R2-dependent PI3K/AKT signaling, while YWHAH connects NAT10/ac4C regulation to T-cell exhaustion and MAPK/ERK-dependent autophagy-associated invasion. SFN shows context-dependent tumor-suppressive or stress-adaptive functions.

The authors note that total 14-3-3 abundance is currently insufficient for mechanistic or translational interpretation. A significant limitation noted is that these proteins are not yet clinically validated as biomarkers or therapeutic targets in colorectal cancer and remain testable hypotheses.

Clinical application of this evidence is currently limited to identifying potential mechanisms for future functional validation. These findings do not support immediate clinical use as established markers or targets.

How this fits prior evidence

This review identifies 14-3-3 proteins as potential biomarkers and therapeutic targets in colorectal cancer, addressing a gap in understanding molecular drivers of the disease. While other evidence highlights risk factors like obesity and the role of deep learning for detection, this review focuses on underlying protein mechanisms. It does not directly relate to findings regarding COVID-19 impacts, immune checkpoint inhibitors, or berberine trials.

Understanding how cancer cells grow and spread is a major hurdle in treating colorectal cancer. A recent review of scientific literature looked at a group of proteins called 14-3-3. These proteins are known to help cells communicate and move, which can unfortunately help cancer progress.

The researchers found that different types of these proteins, such as YWHAG and YWHAZ, may trigger specific pathways that allow tumors to grow or change shape. Other versions, like YWHAE, might be involved in how the cancer releases signals into the body. While these findings are promising, they are currently considered testable hypotheses rather than proven medical tools.

It is important to note that these proteins have not been clinically validated as markers for diagnosis or targets for treatment yet. The study serves as a roadmap for future research to see if these specific proteins can eventually help doctors better understand the disease and develop new ways to fight it.

What this means for you:
Specific 14-3-3 proteins may drive colorectal cancer growth, offering potential targets for future research.

Common questions

What are these 14-3-3 proteins?

These are a group of proteins, including types like YWHAG, YWHAE, and YWHAZ. They help manage cell signals and growth. In the context of colorectal cancer, different versions of these proteins may trigger pathways that allow tumors to grow or spread.

Can these proteins be used to treat cancer right now?

No, these proteins are not yet clinically validated as treatment targets. The current findings are considered testable hypotheses. They provide a starting point for future research to see if they can eventually help in developing new treatments.

How do these proteins affect cancer growth?

Different 14-3-3 isoforms perform different roles. For example, YWHAG is linked to certain growth signals, while YWHAZ may help cells transition and move. Others like YWHAH are linked to how the cancer invades nearby tissue.

Study Details

Study typeSystematic review
EvidenceLevel 1
PublishedAug 2026
View Original Abstract ↓
YWHA/14-3-3 proteins are conserved phosphoserine/phosphothreonine-binding adaptors that coordinate signaling-complex assembly, subcellular localization, stress responses and cell-state transitions. Although often discussed as a single adaptor family, colorectal cancer (CRC) studies suggest that individual YWHA isoforms act through distinct clients, RNA-associated layers and tumor-state contexts. In this narrative and mechanistic review, we synthesized PubMed-indexed CRC literature through 18 May 2026 and appraised CRC-relevant mechanistic modules using an explicit evidence-maturity rubric developed by the authors distinct from formal GRADE assessment. We propose an isoform–client–context framework for interpreting 14-3-3 biology in CRC. YWHAG has been linked to CTTN-dependent Wnt/β-catenin activation, whereas YWHAE/14-3-3ϵ protein has been associated with extracellular-vesicle secretion and EV-associated β-catenin/Wnt outputs. Separately, the YWHAE-encoded lncRNA, hereafter referred to as YWHAE lncRNA, has been proposed to activate KRAS/ERK and PI3K/AKT signaling through a competing endogenous RNA mechanism. YWHAZ participates in epithelial–mesenchymal and G2/M transitions through miR-1-3p- and TRIP13-associated mechanisms. YWHAB supports PIK3R2-dependent PI3K/AKT signaling, whereas YWHAH connects NAT10/ac4C regulation, CD8+ T-cell exhaustion and MAPK/ERK-dependent autophagy-associated invasion. SFN illustrates context-dependent tumor-suppressive or stress-adaptive functions. Overall, total 14-3-3 abundance is insufficient for mechanistic or translational interpretation. Interactomics, phosphoproteomics, spatial profiling, extracellular-vesicle analysis and patient-derived models should be used to prioritize YWHA-dependent candidate mechanisms for functional validation. These modules should currently be regarded as testable biomarker and therapeutic hypotheses, not as clinically validated CRC biomarkers or targets.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.